Israel Hyperlipidemia Drugs Market is Expected to Dominate by Statins Type through 2028
Rising incidence of hyperlipidemia
across the country is expected to drive the growth of the market in the
forecast period, 2024-2028.
According to TechSci
Research report, “Israel Hyperlipidemia Drugs - By Region, Competition, Forecast, and Opportunities, 2028”, the Israel hyperlipidemia drugs market is expected to grow with an
impressive CAGR during the forecast period 2018-2028. The rise in prevalence of
stress, hypertension, hyperlipidemia, and growing awareness amongst the key market
players including manufacturers who are involved in new drug production with
high efficacy, acquisitions, expansions, rise in awareness amongst population
regarding effective drugs, and strategic collaborations, and recent
developments shows the growth of hyperlipidemia drugs market.
However, one of the main contributing factors to the
increasing investment in healthcare facilities. In addition, unhealthy
lifestyles, such as a diet high in salt and saturated fat, sedentary behavior,
and smoking, are also major risk factors for rising lipid and cholestrol which enhanced the growth
of the market in the forecast period.
Additionally, another
important factor contributing to the increasing prevalence of hyperlipidemia is
obesity in Israel as population are more dependent on triglycerides and
cholestrol. Obesity is also a significant risk factor for hyperlipidemia, and
rates of obesity in Israel have been increasing in recent years.
Moreover, one of the
biggest restraining factors is patent expiration. Many of the drugs used to
manage hyperlipidemia are protected by patents, which provide the manufacturer
with a period of exclusivity during which they can charge high prices for their
drugs. However, as these patents expire, generic versions of the drugs become
available, which can significantly reduce the price of the drugs and limit
revenue growth for the manufacturers.
Browse over XX market
data Figures spread through XX Pages and an in-depth TOC on "Israel Hyperlipidemia Drugs Market”
The Israel hyperlipidemia
drugs market can be segmented by drug class, distribution channel, and
region.
Israel
hyperlipidemia drugs market can be segmented by drug class, distribution
channel, and region. By drug class, the market
can be segmented into statins, bile acid sequestrants, cholesterol absorption
inhibitors, pcsk9 inhibitors, combination, and others. In terms of distribution
channel, the market can be segmented into hospital pharmacy, retail pharmacy, and
online pharmacy.
Statins segment
occupied the largest hyperlipidemia drugs market share in 2018, due to lesser
side effects. But is projected to decline in the forecast years due to due to
the arrival of more effective therapies such as PCSK9 inhibitors and bempedoic
acid.
Based on the distribution
channel, the market can be classified into following categories, hospital
pharmacy, retail pharmacy, and online pharmacy. The hospitals pharmacy segment is
expected to show an impressive growth in forecast period due to ease and
availability of the drugs.
Major companies
operating in Israel hyperlipidemia drugs market include:
- Pfizer Pharmaceuticals Israel Ltd
- MERCK SERONO LTD.
- AstraZeneca Israel Inc
- Novartis Pharma Israel Ltd
- Sanofi-Aventis Israel Ltd
- GlaxoSmithKline Israel Ltd.
- Israel B. Abbott.
- Takeda Israel Inc.
- Teva Israel Ltd.
- Servier Israel Inc.
Download Free Sample Report
Customers can also request for 10% free customization on
this report.
“Israel hyperlipidemia drugs market is expected to witness
significant growth during the forecast period on account of increasing number
of hyperlipidemic patients. An increase in awareness of the health risks
associated with cholestrol rise supports the demand for hyperlipidemia drugs
market in Israel. Additionally, various technological advancements, such as the
development of novel drug classes with enhanced efficacy, are acting as other
growth-inducing factors and rise in emergence of players developing new drugs
to prevent from heart failure and heart stroke, is expected to create lucrative
opportunities for the market growth in the next few years” said Mr.
Karan Chechi, Research Director with TechSci Research, a research-based global
management consulting firm.
“Israel Hyperlipidemia Drugs Market, By Drug
Class (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors,
PCSK9 Inhibitors, Combination, and Others), By Distribution Channel (Hospital
Pharmacy, Retail Pharmacy, and Online Pharmacy), By Region, Competition,
Forecast, and Opportunities, 2028.”, has evaluated the future growth
potential of Israel hyperlipidemia drugs market and provides statistics &
information on market size, structure, and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Israel hyperlipidemia drugs market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web: https://www.techsciresearch.com